Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease "ANITA"

Next Previous
X
Search
Trial Profile

A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease "ANITA"

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary) ; Ifosfamide
  • Indications Chondrosarcoma; Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Lipoma; Liposarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Acronyms ANITA

    • Most Recent Events

    • 19 Nov 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.
    • 29 May 2021 Status changed from active, no longer recruiting to discontinued, according to Results published in the European Journal of Cancer.
    • 29 May 2021 Primary endpoint (progression-free survival (PFS)) has not been met, according to Results published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top